Background and Purpose-White matter hyperintensities (WMH) are areas of high signal detected by T2 and fluid-attenuated inversion recovery sequences on brain MRI. Although associated with aging, cerebrovascular risk factors, and cognitive impairment, the pathogenesis of WMH remains unclear. Thus, RNA expression was assessed in the blood of individuals with and without extensive WMH to search for evidence of oxidative stress, inflammation, and other abnormalities described in WMH lesions in brain. Methods-Subjects included 20 with extensive WMH (WMHϩ), 45% of whom had Alzheimer disease, and 18 with minimal WMH (WMHϪ), 44% of whom had Alzheimer disease. All subjects were clinically evaluated and underwent quantitative MRI. Total RNA from whole blood was processed on human whole genome Affymetrix HU133 Plus 2.0 microarrays. RNA expression was analyzed using an analysis of covariance. Results-Two hundred forty-one genes were differentially regulated at Ϯ1.2-fold difference (PϽ0.005) in subjects with
gender, race, years of education, history of hypertension, hyperlipidemia, heart disease, or AD. The diagnosis of AD was made according to the National Institute of Neurological and Communicative Disorders and Stroke /AD and Related Disorders Association criteria. 11 Brain imaging was performed using a 1.5-T GE Signa Horizon LX Echospeed MRI scanner. A T1-weighted coronal 3-dimensional spoiled gradient-recalled echo acquisition and a fluid-attenuated inversion recovery sequence designed to enhance WMH segmentation were used. WMH segmentation and WMH volume measurements were performed as previously described. 12 All the WMHϩ patients had head size-adjusted WMH volume Ͼ75th percentile of a normal population (nϭ20; 11 subjects without dementia and 9 with dementia), and all the WMHϪ subjects had head size-adjusted WMH volume Ͻ25th percentile of a normal population (nϭ18; 10 subjects without dementia and 8 with dementia). Blood collection, RNA purification, and microarray hybridization were performed as previously reported and can be found in Supplemental Methods (available online at http://stroke.ahajournals.org). 10 Demographic data were analyzed with Student t test or Fisher exact tests. Microarray probe-level data were summarized with robust multi-array average algorithm. Quality-control analysis and analysis of covariance were conducted in Partek Genomics Suite (Partek Inc.). A multivariate analysis of covariance was performed to adjust for potential confounders, including sample batch, gender, age, heart disease, hyperlipidemia, and AD. Because a significant number of unknown expressed sequence tags were included, the gene number reported in the results section referred to the number of probe sets, which showed differential gene expression changes. Principal component analysis and unsupervised cluster analysis were then performed in Partek Genomics Suite based on genes identified as differentially regulated to confirm the differential expression pattern between subjects with and without extensive WMH. Genes that were differentially regulated between subjects with and without extensive WMH were further analyzed using Ingenuity Pathways Analysis (IPA 8.0; Ingenuity Systems Inc.). These analyses identified the most statistically significant biological functions or canonical pathways in the data set (PϽ0.1). Fischer exact test was used to calculate a probability value describing the probability that a given biological function was assigned to that data set because of chance alone. Additional pathways were considered to be regulated regardless of the probability value if a regulated gene was a key member of an associated pathway. For example, changes in glutathione S-transferase mu 4 gene expression in the blood of WMHϩ subjects suggested involvement of the glutathione metabolism pathway.
Results
Demographic information for subjects with extensive WMH (WMHϩ) and low WMH (WMHϪ) is given in Table 1 . Subjects with WMHϩ were more likely to have a history of hypertension. However, we found that a history of hypertension had a negligible effect on the analysis of covariance results (not shown). There were no significant differences in age, gender, race, years of education, history of hyperlipidemia, heart disease, or AD between those with and without extensive WMH.
To determine if there is a unique expression profile for WMH, the RNA expression of the blood from subjects with WMHϩ was compared to that of WMHϪ subjects. A multivariate analysis of covariance was performed to control for expression changes accounted for by potential confounders, including batch, gender, age, heart disease, hyperlipidemia, and AD. These factors were included either because they are known risk factors for WMH or because they are known to produce gene expression changes in blood. A total of 50 genes showed a 1.5-fold difference between WMHϩ and WMHϪ subjects, and 241 genes showed a 1. Principal components analysis was performed to evaluate the relationships between WMHϪ and WMHϩ subjects using the 241 gene list. The top 3 primary components accounted for 54.7% of the variance (Figure 1 ). The first principal component alone separated WMHϩ from WMHϪ subjects ( Figure 1 ). Cluster analysis using the 241 gene list also separated WMHϪ subjects from WMHϩ subjects (Figure 2) . A similar separation was also obtained after a principal component analysis and cluster analysis using the more stringent 50 gene list (Supplemental Figure I available online at http://stroke.ahajournals.org).
Only 5 of 241 WMH-associated genes with Ͼ1.2-fold difference and only 1 of 50 with a Ͼ1.5-fold difference were also found in the AD-associated gene list (Supplemental Table III available online at http://stroke.ahajournals.org). Moreover, adding an interaction term for WMH-AD interaction did not change the expression differences for 92% of the originally identified genes. Finally, only 4 of the 241 WMH genes overlapped with our previously identified ischemic stroke-associated genes from similar work with peripheral blood cells (Supplemental Table IV available online at http://stroke.ahajournals.org). 9, 10 Canonical pathway analyses were performed on the 241 gene list. Inflammatory, oxidative, detoxification, hormone, lipid, and carbohydrate metabolism pathways were over-represented (Table 2) . WMH-specific gene expression changes also included brain-related genes involved in long-term potentiation and axon guidance ( Table 2 ). Molecular function association analyses based on a search of the most recent literature yielded similar results (Supplemental Table I available online at http://stroke.ahajournals.org).
Discussion
We found that subjects with extensive WMH had unique blood RNA expression profiles compared to subjects with minimal WMH. Further, the WMH-specific gene expression changes were associated with inflammation, oxidative stress, detoxification, and hormonal responses, and included genes associated with brain repair, long-term potentiation, and axon guidance.
Some studies suggest that the pathogenesis of WMH and AD are related. WMH are associated with impaired memory and executive function, even in healthy older subjects, 13 and may contribute to the progression from normal aging to mild cognitive impairment 14 and from mild cognitive impairment Figure 1 . Principal components analysis (PCA). The 241 genes that were differentially expressed in extensive white matter hyperintensity (WMH) subjects (WMHϩ) vs minimal WMH subjects (WMHϪ) were used for PCA (PϽ0.005 and fold change Ͼ1.2). The top 3 principal components were represented on the x-axis, y-axis, and z-axis. Each symbol represents 1 subject, with red indicating subjects with extensive WMHϩ (nϭ20) and green indicating subjects with minimal WMHϪ (nϭ18). The distance between samples in the 3-dimensional space shows their differences based on the expression pattern. Each of the 2 ellipsoids represents a 2-SD space from the mean of each group of samples. Cluster analysis of white matter hyperintensity (WMH)-associated genes for all subjects. The 241 genes that were differentially expressed in extensive WMH subjects (WMHϩ) vs minimal WMH subjects (WMHϪ) were used for an unsupervised Pearson cluster analysis (PϽ0.005 and fold change Ͼ1.2). Individual genes (nϭ241) are shown on the x-axis and individual subjects (nϭ38) are shown on the y-axis. Genes showing high expression are indicated in red and genes with low expression are indicated in blue. Note that all of the subjects with WMHϩ are clustered separately from low WMH subjects (WMHϪ) and that there is a specific gene expression profile for each with little evidence for subgroups based on these genes. to AD. 15 AD patients are more likely to have extensive WMH than age-matched controls, 16 and AD patients with WMH have greater cognitive impairments than subjects with a similar pathological AD burden, but without extensive WMH. 17 Other studies, however, have not found a relationship between WMH and cognition in AD patients. 18 Thus, it is unclear whether WMH and AD represent different disease processes, whether AD is a consequence of or is exacerbated by WMH, or whether WMH are a consequence of AD or are exacerbated by AD.
Our study partly addresses these questions by showing that WMHϩ subjects with and without AD can have similar gene expression profiles. This suggests that WMH found in normal aging and WMH found in AD patients share a molecular pathology, at least in blood, that is not secondary to AD. The results support the hypothesis that WMH in the aging brain represents a distinct pathological process with a specific cause and is a separate molecular identity despite the fact that the white matter lesions seen on MRI are nonspecific and could represent any number of conditions.
Inflammatory molecules previously shown to be increased in the blood of WMH subjects include lipoprotein-associated phospholipase A2, myeloperoxidase, C-reactive protein, and IL-6. 7, 19 Whole genome studies of postmortem brain white matter in WMH subjects found that 10.6% of WMH-related genes were involved in immune regulation. 20 These inflammatory responses in blood and brain could be the cause of or the result of the endothelial dysfunction and blood-brain barrier breakdown reported in WMHϩ subjects. 21 The expression of several well-known oxidative stress and detoxification genes were also increased in the blood of WMHϩ subjects. Glutathione S-transferase mu 4, which was Glucocorticoid receptor signaling TAF1, PRL, SMARCA2, MAP3K7, IL4
1.7-fold higher in WMHϩ subjects, is a key detoxification enzyme for environmental toxins and products of oxidative stress by conjugation with glutathione. Human microsomal cytochrome b5, which was also higher in the WMHϩ subjects, is an electron transfer component in a number of oxidative reactions and plays an important role in catabolism of xenobiotics and oxidative stress compounds that are relevant to WMH (eg, oxidized lipids). The expression of SLC15A2, a member of solute carrier family 15 (H ϩ /peptide transporter), was also higher in WMHϩ subjects. It translocates small peptides, including drugs and endogenous peptidomimetics such as 5-aminolevulinic acid, across biological membranes. The increased expression of SLC15A2 can protect the brain from 5-aminolevulinic acid toxicity. This could be important because ALAS2 is also higher in WMHϩ subjects, and it is the rate-limiting enzyme for the biosynthesis of 5-aminolevulinic acid.
There are several possible causes for the oxidative stress and detoxification responses observed in WMHϩ subjects. Hypoxia and hypoperfusion have been implicated in the pathogenesis of WMH, which would increase oxidative stress and antioxidant responses. 22 Cardiovascular disease is associated with WMH and is known to increase systemic oxidative stress. ALAS2, which is the rate-limiting enzyme of heme production and was overexpressed in the WMHϩ subjects, could contribute. The correlations of WMH with increased age and with AD may relate, in part or entirely, to the markedly increased oxidative stress associated with age and AD.
There is axonal loss and demyelination in the brains of patients with WMH. Correspondingly, genes involved in axon formation and synaptic plasticity, such as long-term potentiation and axon guidance signaling, were associated with WMH-related expression differences (Table 2 and Supplemental Table I ). For example, microtubule-associated protein 1B, which is expressed 1.9-fold higher in WMHϩ subjects, is involved in axon bundle formation. Homozygous null mutations of microtubule-associated protein 1B in mice cause selective absence of the corpus callosum associated with misguided cortical axons. 23 Thyroid hormone receptor and prolactin, both of which were increased in WMHϩ subjects, play primary roles in promoting oligodendrocyte precursor proliferation for remyelination in adult brain. 24, 25 It is not clear how gene expression changes in blood of WMH subjects relate to central nervous system functionrelated gene expression changes. One possibility is that the gene expression changes in the blood mirror those in the brain. 26 -28 Alternatively, these genes may be expressed in circulating precursor cells or surveillance inflammatory cells in the blood that directly interact with brain cells to promote inflammation-associated injury and/or promote oligodendrocyte, myelin, and axon repair.
This study is limited by its small sample size. Up to 68% of the reported 241 genes could be false-positives based on the current sample size. Future studies on larger cohorts will be needed to replicate the results of this study, search for WMH and AD interactions, and search for gene interactions between WMH and other comorbidities. Whether the changes of gene expression in the blood are the cause or the consequence of the WMH, they may aid in understanding the pathophysiology of WMH and in searching for the cause, monitoring progression, and assessing treatment. 
Supplementary Methods

Blood collection and processing
Whole blood (15 mL) was collected from each subject into six PAXgene tubes via antecubital fossa venipuncture from each subject. PAXgene tubes were frozen at _801C
after 2 h at room temperature. Total RNA was isolated according to the manufacturer's protocol (PAXgene blood RNA kit; Pre-AnalytiX) on an automated workstation Qiacube 
